Understanding blood markers in acute leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at whether a simple blood test can help predict outcomes in patients with newly diagnosed acute leukemia. The test measures the ratio of two proteins in your blood, which might give doctors clues about how the disease will progress.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with acute leukemia.
- You must not have started any treatment for leukemia yet.
- You must not have any chronic inflammatory conditions like rheumatoid arthritis or inflammatory bowel disease.
- You must not have any current acute infections.
- You must not be on chemotherapy or radiation therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if two natural substances in your blood (called cytokines) are linked to how active your leukemia is. It aims to help doctors better understand and possibly predict the disease, which could guide future treatment.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study looks at two simple blood tests in people newly diagnosed with ALL (a type of blood cancer) to see if these tests can help predict how the disease might progress. It may help doctors understand your condition better and could lead to more personalized care.
This study looks at routine blood test results (called CBC) in people who have just been diagnosed with acute lymphoblastic leukemia (ALL), a type of blood cancer. The goal is to see if certain blood levels can help doctors understand the disease better and guide treatment.
This trial studies whether the levels of certain proteins and blood clotting factors in your blood can help doctors understand acute myeloid leukemia better. It may lead to better ways to monitor the disease and its effects on your body.
This study looks at special markers in bone marrow fluid to predict how well chemotherapy will work for newly diagnosed acute myeloid leukemia (AML). By identifying these markers early, doctors may be able to choose the best treatment plan for each patient.
Hear when a new Patients with Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.